Trial Profile
Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 10 Apr 2013 Planned End Date changed from 1 Aug 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 10 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 27 Oct 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov